CD19 and acute lymphoblastic leukemia: Concurrently, researchers at the NCI conducted a phase I clinical trial of CD19 CART cells containing a CD28 costimulatory endodomain in pediatric and young adult patients with a reported response rate for B-ALL of 70%, but T cell persistence was not seen (Lee et al. 2015).